AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7573630 — intervention group
Group type: COMPARATOR
Intervention: 12-month therapeutic community program
Number of subjects: 628
Study 7573630 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month relapse prevention program
Number of subjects: 628
Study 7573630 — intervention group
Group type: COMPARATOR
Intervention: 6-month relapse prevention program
Number of subjects: 628
Study 1767648 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous blood using the cell saver
Number of subjects: 40
Study 1767648 — intervention group
Group type: COMPARATOR
Intervention: Homologous bank blood
Number of subjects: 40
Study 7355429 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulant (AC) treatment
Number of subjects: 156
Study 7355429 — intervention group
Group type: COMPARATOR
Intervention: Anti-platelet therapy
Number of subjects: 156
Study 7355429 — intervention group
Group type: COMPARATOR
Intervention: Natural history of untreated TIA/RIND
Number of subjects: 156
Study 31515418 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneal cross-linking (CXL) treatment
Number of subjects: 60
Study 31515418 — intervention group
Group type: COMPARATOR
Intervention: Standard care (spectacles or contact lenses)
Number of subjects: 60
Study 28766264 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (20 mg/kg lean body mass)
Number of subjects: 9
Study 28766264 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 25671224 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderation Only
Number of subjects: 305
Study 25671224 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstinence Only
Number of subjects: 305
Study 25671224 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderation to Abstinence
Number of subjects: 305
Study 25671224 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstinence to Moderation
Number of subjects: 305
Study 24820263 — intervention group
Group type: EXPERIMENTAL
Intervention: Cued attention with reward-prospect
Number of subjects: 0
Study 24820263 — intervention group
Group type: COMPARATOR
Intervention: Cued attention without reward-prospect
Number of subjects: 0
Study 22716976 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine
Number of subjects: 288
Study 22716976 — intervention group
Group type: COMPARATOR
Intervention: Ritonavir-boosted lopinavir
Number of subjects: 288
Study 20619242 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (angiotensin II receptor blocker)
Number of subjects: 300
Study 20619242 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 20619242 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 300
Study 17364552 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5 mg daily for up to 5 years
Number of subjects: 4000
Study 17364552 — intervention group
Group type: COMPARATOR
Intervention: Anastrozole 1 mg daily for up to 5 years
Number of subjects: 4000
Study 16376249 — intervention group
Group type: EXPERIMENTAL
Intervention: Wound compression (inflatable cuff placed over the wound)
Number of subjects: 105
Study 16376249 — intervention group
Group type: COMPARATOR
Intervention: Control (wound drainage)
Number of subjects: 105
Study 12554545 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive therapy self-help program (n = 144)
Number of subjects: 144
Study 12554545 — intervention group
Group type: COMPARATOR
Intervention: No-access control group (n = 155)
Number of subjects: 144
Study 9522144 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 0.6 mg kg‐1
Number of subjects: 36
Study 9522144 — intervention group
Group type: COMPARATOR
Intervention: Pethidine 0.6 mg kg‐1
Number of subjects: 36
Study 9522144 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 8138636 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure lavender oil
Number of subjects: 635
Study 8138636 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic lavender oil
Number of subjects: 635
Study 8138636 — intervention group
Group type: COMPARATOR
Intervention: Inert substance
Number of subjects: 635
Study 2724233 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal steroid administration
Number of subjects: 183
Study 2724233 — intervention group
Group type: EXPERIMENTAL
Intervention: Male infants
Number of subjects: 183
Study 2724233 — intervention group
Group type: EXPERIMENTAL
Intervention: Female infants
Number of subjects: 183
Study 29969938 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week group-based cognitive remediation
Number of subjects: 27
Study 29969938 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 27
Study 27246567 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline (0, 1, 2 mg/d)
Number of subjects: 44
Study 27246567 — intervention group
Group type: COMPARATOR
Intervention: Varenicline (1 and 2 mg/d)
Number of subjects: 44
Study 27246567 — intervention group
Group type: COMPARATOR
Intervention: High-dose alcohol (0.08 g/dl)
Number of subjects: 44
Study 27246567 — intervention group
Group type: COMPARATOR
Intervention: Nonalcohol control beverage
Number of subjects: 44
Study 26420181 — intervention group
Group type: EXPERIMENTAL
Intervention: HMB/Arg/Gln supplementation
Number of subjects: 23
Study 26420181 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 23
Study 24016495 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine early eptifibatide
Number of subjects: 9406
Study 24016495 — intervention group
Group type: COMPARATOR
Intervention: Delayed provisional use of eptifibatide
Number of subjects: 9406
Study 19852709 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 year of coaching to adopt health-enhancing physical activity (moderately intensive, 30 min/day, > 4 days/week)
Number of subjects: 228
Study 19852709 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 228
Study 18840370 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsule formulation of meclofenoxate hydrochloride 200 mg
Number of subjects: 24
Study 18840370 — intervention group
Group type: COMPARATOR
Intervention: Tablet formulation of meclofenoxate hydrochloride 200 mg
Number of subjects: 24
Study 17054457 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant GH for 6 months
Number of subjects: 16
Study 17054457 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 16
Study 17054457 — intervention group
Group type: COMPARATOR
Intervention: Baseline measurements
Number of subjects: 16
Study 12818406 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 ml of linseed oil (rich in ALA) per day (n=50)
Number of subjects: 76
Study 12818406 — intervention group
Group type: COMPARATOR
Intervention: 15 ml of safflower oil (rich in LA) per day (n=26)
Number of subjects: 76
Study 11933306 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiant heat therapy
Number of subjects: 0
Study 11933306 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 0
Study 8775403 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic ANF (0.01 microgram.kg.min, Anaritide, Wyeth Laboratories)
Number of subjects: 6
Study 8775403 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (Met)
Number of subjects: 6
Study 8775403 — intervention group
Group type: EXPERIMENTAL
Intervention: ANF
Number of subjects: 6
Study 1538208 — intervention group
Group type: EXPERIMENTAL
Intervention: brief pulse right unilateral ECT
Number of subjects: 33
Study 1538208 — intervention group
Group type: EXPERIMENTAL
Intervention: brief pulse left unilateral ECT
Number of subjects: 33
Study 1538208 — intervention group
Group type: EXPERIMENTAL
Intervention: brief pulse bilateral ECT
Number of subjects: 33
Study 6240599 — intervention group
Group type: EXPERIMENTAL
Intervention: IK‐6‐Inhaletten (0.1 mg Fenoterol + 0.04 mg Ipratropiumbromide)
Number of subjects: 39
Study 6240599 — intervention group
Group type: COMPARATOR
Intervention: SCH 1000‐Inhaletten (0.2 mg Ipratropiumbromide)
Number of subjects: 39
Study 29629828 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based cognitive-behavioral therapy (T-CBT)
Number of subjects: 39
Study 29478494 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified nonreactive varieties of oats (15-40g)
Number of subjects: 177
Study 29478494 — intervention group
Group type: COMPARATOR
Intervention: Placebo (gluten-free food)
Number of subjects: 177
Study 27084301 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based Cognitive Behavioral Therapy (CBT)
Number of subjects: 0
Study 27084301 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based Compassionate Mind Training (CMT)
Number of subjects: 0
Study 20626584 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri (2×10(8) CFU/day)
Number of subjects: 60
Study 20626584 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 22331396 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam (two different concentrations)
Number of subjects: 8
Study 21154024 — intervention group
Group type: EXPERIMENTAL
Intervention: PMT group (intervention)
Number of subjects: 166
Study 21154024 — intervention group
Group type: COMPARATOR
Intervention: Non-PMT group (attention control)
Number of subjects: 166
Study 17573446 — intervention group
Group type: EXPERIMENTAL
Intervention: Roflumilast 500 microg once daily for 4 weeks
Number of subjects: 38
Study 17573446 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 15670372 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil-releasing microspheres (130 mg) with early radiotherapy (59.4 Gy)
Number of subjects: 95
Study 15670372 — intervention group
Group type: COMPARATOR
Intervention: Early radiotherapy alone (59.4 Gy)
Number of subjects: 95
Study 15670372 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil-releasing microspheres (130 mg) with early radiotherapy (59.4 Gy) in patients with complete resection
Number of subjects: 95
Study 15670372 — intervention group
Group type: COMPARATOR
Intervention: Early radiotherapy alone (59.4 Gy) in patients with complete resection
Number of subjects: 95
Study 12191977 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin (target INR of 1.4 to 1.9)
Number of subjects: 107
Study 12191977 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study 12191977 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 107
Study 9807978 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice
Number of subjects: 12
Study 9807978 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 12
Study 7612086 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant Crib Air (ICA) apparatus
Number of subjects: 21
Study 2238574 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG)
Number of subjects: 30
Study 2238574 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 30
Study 190971 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term hospitalization
Number of subjects: 141
Study 190971 — intervention group
Group type: COMPARATOR
Intervention: Short-term hospitalization
Number of subjects: 141
Study 31691810 — intervention group
Group type: EXPERIMENTAL
Intervention: TJ-14
Number of subjects: 22
Study 29649425 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 g freeze‐dried polyphenol‐rich whole grape powder (GP)
Number of subjects: 20
Study 29649425 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 weeks of daily GP consumption
Number of subjects: 20
Study 29649425 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 20
Study 28103829 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous hydration with three litres of Hartmann's solution between midnight and 8 am before kidney donation
Number of subjects: 86
Study 28103829 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intravenous hydration)
Number of subjects: 86
Study 28103829 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous hydration
Number of subjects: 86
Study 26122235 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiviral therapy
Number of subjects: 54
Study 26122235 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antiviral therapy)
Number of subjects: 54
Study 26122235 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained virus response to antiviral therapy
Number of subjects: 54
Study 26122235 — intervention group
Group type: EXPERIMENTAL
Intervention: No response to antiviral therapy
Number of subjects: 54
Study 23614999 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-663068 monotherapy
Number of subjects: 0
Study 21923713 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day sequential therapy (pantoprazole 40 mg + amoxicillin 1000 mg twice a day for 5 days, then pantoprazole 40 mg + clarithromycin 500 mg + metronidazole 500 mg twice a day for 5 days)
Number of subjects: 409
Study 21923713 — intervention group
Group type: COMPARATOR
Intervention: 14-day PPI-based triple therapy (pantoprazole 40 mg + amoxicillin 1000 mg + clarithromycin 500 mg twice a day for 14 days)
Number of subjects: 409
Study 21923713 — intervention group
Group type: EXPERIMENTAL
Intervention: Both therapies
Number of subjects: 409
Study 18312035 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (anodal stimulation of left and right DLPFC)
Number of subjects: 24
Study 18312035 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 24
Study 16400951 — intervention group
Group type: EXPERIMENTAL
Intervention: Qingkailing soft capsules (1.6 g, 4 times a day)
Number of subjects: 129
Study 16400951 — intervention group
Group type: COMPARATOR
Intervention: Shuanghuanglian kou fu liquid (control)
Number of subjects: 129
Study 16400951 — intervention group
Group type: EXPERIMENTAL
Intervention: Qingkailing soft capsules
Number of subjects: 129
Study 11817760 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of diazepam
Number of subjects: 60
Study 11817760 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 9785271 — intervention group
Group type: EXPERIMENTAL
Intervention: Total sleep time of 0 min (0 h TIB)
Number of subjects: 8
Study 9785271 — intervention group
Group type: EXPERIMENTAL
Intervention: Total sleep time of 113 min (2 h TIB)
Number of subjects: 8
Study 9785271 — intervention group
Group type: EXPERIMENTAL
Intervention: Total sleep time of 218 min (4 h TIB)
Number of subjects: 8
Study 9785271 — intervention group
Group type: EXPERIMENTAL
Intervention: Total sleep time of 427 min (8 h TIB)
Number of subjects: 8
Study 7881956 — intervention group
Group type: EXPERIMENTAL
Intervention: Colour Doppler ultrasonography assessment before and after operation
Number of subjects: 38
Study 7881956 — intervention group
Group type: COMPARATOR
Intervention: Clinical examination only (Control group)
Number of subjects: 38
Study 2198177 — intervention group
Group type: EXPERIMENTAL
Intervention: Early GMH (evident on cranial ultrasonogram before the 12th postnatal hour)
Number of subjects: 0
Study 2198177 — intervention group
Group type: EXPERIMENTAL
Intervention: Early GMH
Number of subjects: 0
Study 329975 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF (cyclophosphamide, Adriamycin, 5-fluorouracil)
Number of subjects: 113
Study 329975 — intervention group
Group type: COMPARATOR
Intervention: CMFVP (cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, prednisone)
Number of subjects: 113
Study 31855680 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral contraceptive (1.5 mg estradiol and 2.5 mg nomegestrolacetate)
Number of subjects: 69
Study 31855680 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 31855680 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral contraceptive (COC)
Number of subjects: 69
Study 30872105 — intervention group
Group type: EXPERIMENTAL
Intervention: High meat group (minimum of 2 servings/week of red or processed meat)
Number of subjects: 214
Study 30872105 — intervention group
Group type: COMPARATOR
Intervention: Low meat group (not more than 1 serving per month of red or processed meat)
Number of subjects: 214
Study 28618424 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive sealing
Number of subjects: 61
Study 28618424 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic sealing
Number of subjects: 61
Study 26592847 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin complexed with phosphatidylserine in phytosome form
Number of subjects: 44
Study 26592847 — intervention group
Group type: COMPARATOR
Intervention: Pure phosphatidylserine
Number of subjects: 44
Study 23989087 — intervention group
Group type: EXPERIMENTAL
Intervention: MIXED hemodiafiltration at Qb 250 ml/min
Number of subjects: 38
Study 23989087 — intervention group
Group type: COMPARATOR
Intervention: PRE hemodiafiltration at Qb 250 ml/min
Number of subjects: 38
Study 23989087 — intervention group
Group type: EXPERIMENTAL
Intervention: MIXED hemodiafiltration at Qb 300 ml/min
Number of subjects: 38
Study 23989087 — intervention group
Group type: COMPARATOR
Intervention: PRE hemodiafiltration at Qb 300 ml/min
Number of subjects: 38
Study 23989087 — intervention group
Group type: EXPERIMENTAL
Intervention: MIXED hemodiafiltration
Number of subjects: 38
Study 21473660 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological family-based intervention (2 sessions by a health psychologist, plus a 15-minute follow-up call)
Number of subjects: 121
Study 21473660 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological family-based intervention (specifically for those with A1C>9.5%)
Number of subjects: 121
Study 21473660 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological family-based intervention
Number of subjects: 121
Study 21473660 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual diabetes care)
Number of subjects: 121
Study 19419350 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline (HS) 4 ml/kg
Number of subjects: 50
Study 19419350 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyethyl starch (HES) 4 ml/kg
Number of subjects: 50
Study 16765146 — intervention group
Group type: EXPERIMENTAL
Intervention: Benazepril or Imidapril
Number of subjects: 509
Study 16765146 — intervention group
Group type: COMPARATOR
Intervention: Control group (CC genotype)
Number of subjects: 509
Study 16765146 — intervention group
Group type: EXPERIMENTAL
Intervention: A6547G polymorphism (AA, AG, GG genotypes)
Number of subjects: 509
Study 15037404 — intervention group
Group type: EXPERIMENTAL
Intervention: Blastocyst-stage embryo transfer
Number of subjects: 54
Study 15037404 — intervention group
Group type: COMPARATOR
Intervention: Day 2-3 embryo transfer
Number of subjects: 54
Study 11688080 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplement in the form of a fortified powder fruit drink, consumed 25 grams per school day for six months.
Number of subjects: 0
Study 11688080 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group), details not specified.
Number of subjects: 0
Study 9264076 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.25, 0.5, or 1.0 g/kg)
Number of subjects: 5
Study 9264076 — intervention group
Group type: EXPERIMENTAL
Intervention: Marijuana (4.8 or 16 puffs of 3.55% THC)
Number of subjects: 5
Study 9264076 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 9264076 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 5
Study 7888296 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate 800 mg
Number of subjects: 12
Study 7888296 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine hydrochloride 300 mg
Number of subjects: 12
Study 7888296 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3250317 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg o.d.)
Number of subjects: 74
Study 3250317 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol CR (100 mg o.d.)
Number of subjects: 74
Study 3250317 — intervention group
Group type: COMPARATOR
Intervention: Atenolol and Metoprolol CR
Number of subjects: 74
Study 3250317 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol CR
Number of subjects: 74
Study 3250317 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 74
Study 3250317 — intervention group
Group type: EXPERIMENTAL
Intervention: No preference
Number of subjects: 74
Study 29931665 — intervention group
Group type: EXPERIMENTAL
Intervention: US-guided IBPB (U)
Number of subjects: 108
Study 29931665 — intervention group
Group type: EXPERIMENTAL
Intervention: PNS-confirmation IBPB (N)
Number of subjects: 108
Study 29931665 — intervention group
Group type: EXPERIMENTAL
Intervention: US-guided, PNS-confirmed IBPB (dual guidance; NU)
Number of subjects: 108
Study 29931665 — intervention group
Group type: COMPARATOR
Intervention: All techniques (U, N, NU)
Number of subjects: 108
Study 26501496 — intervention group
Group type: EXPERIMENTAL
Intervention: Challenging Horizons Program‐after school version (CHP‐AS)
Number of subjects: 326
Study 26501496 — intervention group
Group type: COMPARATOR
Intervention: Challenging Horizons Program‐mentoring version (CHP‐M)
Number of subjects: 326
Study 26501496 — intervention group
Group type: COMPARATOR
Intervention: Community care (CC)
Number of subjects: 326
Study 25687836 — intervention group
Group type: EXPERIMENTAL
Intervention: Acticoat™
Number of subjects: 96
Study 25687836 — intervention group
Group type: EXPERIMENTAL
Intervention: Acticoat™ with Mepitel™
Number of subjects: 96
Study 25687836 — intervention group
Group type: COMPARATOR
Intervention: Mepilex Ag™
Number of subjects: 96
Study 23564211 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 15 mg + Verapamil 120 mg (P-gp blocker)
Number of subjects: 13
Study 23564211 — intervention group
Group type: COMPARATOR
Intervention: Cetirizine 15 mg
Number of subjects: 13
Study 23564211 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 23564211 — intervention group
Group type: COMPARATOR
Intervention: Verapamil 120 mg
Number of subjects: 13
Study 20224056 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose alteplase (0.90 ± 0.02 mg/kg)
Number of subjects: 241
Study 20224056 — intervention group
Group type: COMPARATOR
Intervention: Lower dose alteplase (0.72 ± 0.07 mg/kg)
Number of subjects: 241
Study 20224056 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose alteplase (0.90 ± 0.02 mg/kg) in patients ≥ 70 years old
Number of subjects: 241
Study 20224056 — intervention group
Group type: COMPARATOR
Intervention: Lower dose alteplase (0.72 ± 0.07 mg/kg) in patients ≥ 70 years old
Number of subjects: 241